

Provet Veteriner Ürünleri San. ve Tic. A.Ş.
Balance Sheet as at 31 March 2020
All amounts are in Turkish Lira unless stated otherwise

Particulars	Note No.	As at 31 March 2020	As at 31 March 2019
ASSETS			
1 Non-current assets			
(a) Property, plant and equipment	3	1,41,45,963	1,43,91,007
(b) Capital work in progress	3	-	5,57,699
(c) Other Intangible assets	3	2,74,911	12,344
(d) Financial assets			
(i) Investments	4	1,34,50,000	1,34,50,000
		2,78,70,875	2,84,11,050
2 Current assets			
(a) Inventories	5	1,89,53,347	1,30,08,680
(b) Financial assets			
(i) Investments	6	16,50,260	1,07,554
(ii) Trade receivables	7	3,49,71,921	2,59,12,950
(iii) Cash and cash equivalents	8	1,19,32,232	1,19,67,244
(iv) Loans	9	38,38,036	1,93,115
(c) Other current assets	10	10,30,070	14,04,183
		7,23,75,865	5,25,93,726
TOTAL ASSETS		10,02,46,740	8,10,04,777
EQUITY AND LIABILITIES			
1 Equity			
(a) Equity share capital	11	20,00,000	20,00,000
(b) Other equity	12	2,77,31,147	2,04,21,440
		2,97,31,147	2,24,21,440
2 Non-current liabilities			
(a) Financial liabilities			
(i) Borrowings	13	5,24,875	-
(ii) Lease liability	31	11,84,108	-
(b) Long-term provisions	14	7,60,698	4,75,222
		24,69,681	4,75,222
3 Current liabilities			
(a) Financial liabilities			
(i) Short-term borrowings	15	4,52,47,978	3,97,83,715
(ii) Trade payables	16	1,63,74,869	1,41,47,891
(iii) Lease liability	31	64,399	-
(iv) Other financial liabilities	17	4,75,125	2,72,108
(b) Other current liabilities	18	26,53,223	25,91,847
(c) Provisions	19	1,35,494	39,869
(d) Deferred tax liabilities (net)	20	5,17,218	9,53,372
(e) Current tax liabilities (net)	21	25,77,606	3,19,313
		6,80,45,913	5,81,08,114
TOTAL EQUITY AND LIABILITIES		10,02,46,740	8,10,04,777

See accompanying notes to the financial statements 2

As per our report of event date
Deloitte Turkey
Auditors

Place : Istanbul
Date : 8th May 2020

For and on Behalf of the Board of Directors

Manish Gupta
Director
Thane, 6th May 2020



Provet Veteriner Ürünleri San. ve Tic. A.Ş.
Statement of Profit and Loss for the year ended 31 March 2020
All amounts are in Turkish Lira unless stated otherwise

Particulars		Note No.	Year Ended 31 March 2020	Year Ended 31 March 2019
(I)	Revenue From Operations	22	7,98,17,501	4,62,30,724
(II)	Other Income	23	13,77,273	18,88,115
Total Income (I+ II)			8,11,94,774	4,81,18,840
(III)	EXPENSES			
	Cost of materials consumed	24	3,12,37,794	1,37,34,113
	Changes in inventories of finished goods and work-in-progress & intermediates	25	28,20,543	28,20,543
	Employee benefits expense	26	1,31,75,137	95,28,785
	Finance costs	27	18,63,039	13,42,891
	Depreciation and amortization expense	28	29,30,533	25,09,482
	Other expenses	29	1,93,83,365	1,90,48,545
Total expenses (III)			7,14,10,411	4,89,84,358
(IV)	Profit before tax		97,84,363	(8,65,519)
(V)	Tax expense:	30		
	(1) Current tax		24,43,963	3,19,313
	(2) Previous tax		-	(2,52,226)
	(2) Deferred tax		(3,64,967)	12,81,350
Total Tax (V)			20,78,996	13,48,437
(VI)	Profit (Loss) for the period (IV-V)		77,05,367	(22,13,956)
(VII)	Other Comprehensive Income		(1,43,271)	(1,22,739)
(VIII)	Total Comprehensive Income for the period (VI+VII)		75,62,096	(23,36,695)
(IX)	Earnings per equity share:	32		
	(1) Basic		37,810	(11,683)
	(2) Diluted		37,810	(11,683)
See accompanying notes to the financial statements		2		

As per our report of event date
Deloitte Turkey
Auditors

Place : Istanbul
Date : 8th May 2020

For and on Behalf of the Board of Directors

Manish
Manish Gupta
Director

Thane, 6th May 2020



Provet Veteriner Döğlereri San. ve Tic. A.Ş.
Statement of Changes in Equity (SOCE) for the period ended 31 March, 2020
All amounts are in Turkish Lira unless stated otherwise

(a) Equity share capital

Particulars	As at 31 March, 2020		As at 31 March, 2019	
	No. of Shares	Amount	No. of Shares	Amount
Balance at the beginning of the reporting period	200	20,00,000	200	20,00,000
Changes in equity share capital during the year/period	-	-	-	-
Balance at the end of the reporting period	200	20,00,000	200	20,00,000

(b) Other Equity

Reserves and Surplus	Year ended 31st March 2020					Year ended 31st March 2019						
	General reserve	Revaluation reserve	Capital reserve	OCI	Retained Earnings	Total	General reserve	Revaluation reserve	Capital reserve	OCI	Retained Earnings	Total
Opening balance	1,22,53,825	51,82,487	49,339	(25,356)	29,61,344	2,04,21,449	1,22,53,825	51,82,487	49,339	67,185	21,75,300	2,37,58,135
Profit for the period	-	-	-	(1,43,271)	74,52,978	73,09,707	-	-	-	(1,22,739)	(22,13,956)	(23,36,695)
Closing balance	1,22,53,825	51,82,487	49,339	(1,68,627)	1,04,14,322	2,07,21,147	1,22,53,825	51,82,487	49,339	(25,554)	29,61,344	2,04,21,449

The accompanying notes are an integral part of the financial statements.

As per our report attached date
Deloitte Turkey
Auditors

Finco : İstanbul
Date : 08 May 2020

For and on Behalf of the Board of Directors

M. Gökçe
Mehmet Gökçe
Director

Thurs, 6 May 2020



Provet Veteriner Ürünleri San. ve Tic. A.Ş.
Notes forming part of the financial statements
Notes

1 Legal status and principal activities

Provet Veteriner Ürünleri San. ve Tic. A.Ş. (the Company) is a company duly organised and incorporated in accordance with the laws of Turkey and is engaged in the manufacturing and marketing of pharmaceuticals products.

2 Significant accounting policies

2.1 Changes in accounting policies and disclosures:

New and amended standards

The Company applied Ind AS 116 Leases for the first time. The nature and effect of the changes as a result of adoption of this new accounting standard is described below.

Several other amendments apply for the first time for the year ending 31 March 2019, but do not have an impact on the consolidated financial statements of the Company. The Company has not early adopted any standards, amendments that have been issued but are not yet effective/notified.

Ind AS 116 Leases

Ind AS 116 supersedes Ind AS 17 Leases including its appendices (Appendix C of Ind AS 17 Determining whether an Arrangement contains a Lease, Appendix A of Ind AS 17 Operating Leases-Incentives and Appendix B of Ind AS 17 Evaluating the Substance of Transactions Involving the Legal Form of a Lease). The standard sets out the principles for the recognition, measurement, presentation and disclosure of leases and requires lessees to recognise most leases on the balance sheet.

Lessor accounting under Ind AS 116 is substantially unchanged from Ind AS 17. Lessors will continue to classify leases as either operating or finance leases using similar principles as in Ind AS 17. Therefore, Ind AS 116 does not have an impact for leases where the Company is the lessor.

The Company adopted Ind AS 116 using the full retrospective method of adoption, with the date of initial application on 1 April 2019. The Company elected to use the transition practical expedient to not reassess whether a contract is, or contains, a lease at 1 April 2019. Instead, the Company applied the standard only to contracts that were previously identified as leases applying Ind AS 17 and Appendix C of Ind AS 17 at the date of initial application. The Company also elected to use the recognition exemptions for lease contracts that, at the commencement date, have a lease term of 12 months or less and do not contain a purchase option (short-term leases), and lease contracts for which the underlying asset is of low value (low-value assets).

2.2 Basis of accounting and preparation of financial statements

The Financial Statements have been prepared on accrual basis under the historical cost convention except for certain categories of fixed assets that are carried at revalued amounts.

The financial statements of Provet Veteriner Ürünleri San. ve Tic. A.Ş. (the Company) have been prepared, in accordance with Indian Accounting Standards ("Ind AS") notified under the Companies (Indian Accounting Standards) Rules, 2015

2.3 Tangible fixed assets

Fixed assets are carried at cost less accumulated depreciation and impairment losses, if any. The cost of fixed assets comprise its purchase price net of any trade discounts and rebates, any import duties and other taxes (other than the subsequently recoverable from the tax authorities), any directly attributable expenditure on making the asset ready for its intended use, other incidental expenses and interest on borrowings attributable to acquisition of qualifying fixed assets to the date the asset is ready for its intended use. Exchange differences arising on restatement/ settlement of long-term foreign currency borrowings relating to acquisition of depreciable fixed assets are adjusted to the cost of the respective assets and depreciated over the remaining useful life of such assets. Subsequent expenditure relating to fixed assets is capitalised only if such expenditure results in an increase in the future benefits from such asset beyond its previously assessed standard of performance.

M

A

2.4 Intangible fixed assets

Intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is their fair value at the date of acquisition. Following initial recognition, intangible assets are carried at cost less any accumulated amortisation and accumulated impairment losses. Internally generated intangibles, excluding capitalised development costs, are not capitalised and the related expenditure is reflected in profit or loss in the period in which the expenditure is incurred.

The useful lives of intangible assets are assessed as either finite or indefinite.

Intangible assets with finite lives are amortised over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortisation period and the amortisation method for an intangible asset with a finite useful life are reviewed at least at the end of each reporting period. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are considered to modify the amortisation period or method, as appropriate, and are treated as changes in accounting estimates. The amortisation expense on intangible assets with finite lives is recognised in the statement of profit and loss unless such expenditure forms part of carrying value of another asset.

Intangible assets with indefinite useful lives are not amortised, but are tested for impairment annually, either individually or at the cash-generating unit level. The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis.

An intangible asset is derecognised upon disposal (i.e., at the date the recipient obtains control) or when no future economic benefits are expected from its use or disposal. Any gain or loss arising upon derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the statement of profit and loss, when the asset is derecognised.

2.5 Depreciation

Depreciation is provided under the SLM method based on the useful lives

Name of the Assets	Useful life
Freehold land	-
Factory building	21 years
Furniture and fixtures	5 years
Office equipments	5 years
Computers	4 years
Plant and machinery	10 years
Vehicles	8 years

2.6 Impairment of assets

The carrying values of assets / cash generating units at each balance sheet date are reviewed for impairment if any indication of impairment exists. The following intangible assets are tested for impairment each financial period even if there is no indication that the asset is impaired:

(a) an intangible asset that is not yet available for use; and (b) an intangible asset that is amortised over a period exceeding ten periods from the date when the asset is available for use.

If the carrying amount of the assets exceed the estimated recoverable amount, an impairment is recognised for such excess amount. The impairment loss is recognised as an expense in the Statement of Profit and Loss, unless the asset is carried at revalued amount, in which case any impairment loss of the revalued asset is treated as a revaluation decrease to the extent a revaluation reserve is available for that asset.

The recoverable amount is the greater of the net selling price and their value in use. Value in use is arrived at by discounting the future cash flows to their present value based on an appropriate discount factor.

When there is indication that an impairment loss recognised for an asset (other than a revalued asset) in earlier accounting periods no longer exists or may have decreased, such reversal of impairment loss is recognised in the Statement of Profit and Loss, to the extent the amount was previously charged to the Statement of Profit and Loss. In case of revalued assets such reversal is not recognised.

2.7 Inventory

Inventories comprises of Raw material, Work-in-progress and intermediates, packing material & finished goods. These are valued at the lower of cost and net realizable value. Cost is determined as follows:-

(i) Raw materials & packing material :

At purchase cost including other cost incurred in bringing materials to their present location and condition

(ii) Work in process, intermediates & Finished goods :

At material cost, conversion cost and appropriate share of production overheads

M

AK

2.8 Revenue recognition

On 01 April 2018, the Company adopted IND AS 115, Revenue from Contracts with Customers using the modified retrospective method. The company applied the new standard to all contracts with customers within the scope of the standard that were in effect on 01 April 2018. However, no amount was recognized as there was no impact of the cumulative effect of initially applying the new standard as an adjustment to the opening balance of retained earnings. Comparative information for prior periods has not been restated and continues to be reported under the accounting standards in effect for those periods.

The new standard requires to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration that it expects to be entitled to in exchange for those goods or services. The new standard introduces a 5-step model to recognize revenue when the control is transferred: identify the contract with a customer, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize revenue when or as the performance obligations are satisfied.

Revenue from export sales is recognized on the basis of the shipping bills for exports. Revenue from domestic sales is recognized based on the passage of title of goods which generally coincides with dispatch. Sales are stated net of discounts, other taxes, and sales returns.

Dividend income is recognised when the right to receive the same is established.

Interest income is recognised on an accrual basis.

2.9 Employee benefits

Short term employee benefits are accrued based on the terms of employment when services are rendered by the employees and charged as an expense to the statement of profit and loss.

Leave balances standing to the credit of the employees that are expected to be availed in the short term are provided for on full cost basis.

2.10 Foreign currency transactions

Initial recognition

Transactions in foreign currencies entered into by the Company are accounted at the exchange rates prevailing on the date of the transaction or at rates that closely approximate the rate at the date of the transaction.

Foreign currency monetary items of the Company outstanding at the Balance Sheet date are restated at the period-end rates. Non monetary items of the Company are carried at historical cost. Revenue and expenses are translated at the average exchange rates prevailing during the period.

Treatment of exchange differences

Exchange differences arising on settlement / restatement of foreign currency monetary assets and liabilities of the Company are recognised as income or expense in the statement of profit and loss.

2.11 Taxes on income

Income tax comprises the current tax provision. Current tax is the amount of tax payable on the taxable income for the period

2.12 Earnings per share (EPS)

In determining the Earnings per share, the Company considers the net profit after tax. The number of shares used in computing Basic Earnings per share is the weighted average number of equity shares outstanding during the period. The number of shares used in computing Diluted Earnings per share comprises the weighted average number of equity shares considered for deriving Basic earnings per share and also the weighted average number of equity shares that could have been issued on the conversion of all dilutive potential equity shares. Dilutive potential equity shares are deemed converted as of the beginning of the period unless issued at a later date.

2.13 Provisions and contingencies

A provision is recognized when the Company has a present legal or constructive obligation as a result of past event and it is probable that an outflow of resources will be required to settle the obligation, in respect of which reliable estimate can be made. Provisions (excluding retirement benefits) are not discounted to its present value and are determined based on best estimate required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimate. Contingent liabilities are not recognized but are disclosed in the notes to financial statements.

4

2.14 Use of estimates

The preparation of the financial statements in conformity with the Accounting Standards generally accepted in India requires that the Management makes estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities as at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Management believes that the estimates used in preparation of financial statement are prudent and reasonable. Actual results could differ from those estimates and the estimates are recognised in the period in which the results are known/materialise.

2.15 Segment

Segments have been identified taking into account the nature of services, the differing risks and returns, the organizational structure and the internal reporting system.

2.16 Insurance claims

Insurance claims are accounted for on the basis of claims admitted / expected to be admitted and to the extent that there is no uncertainty in receiving the claims.

2.17 Borrowing costs

Borrowing costs include interest, amortisation of ancillary costs incurred and exchange differences arising from foreign currency borrowings to the extent they are regarded as an adjustment to the interest cost. Costs in connection with the borrowing of funds to the extent not directly related to the acquisition of qualifying assets are charged to the Statement of Profit and Loss over the tenure of the loan.

2.18 Leases

At the commencement date of the lease, the Company recognises lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including insubstance fixed payments) less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Company and payments of penalties for terminating the lease, if the lease term reflects the Company exercising the option to terminate. Variable lease payments that do not depend on an index or a rate are recognised as expenses (unless they are incurred to produce inventories) in the period in which the event or condition that triggers the payment occurs. In calculating the present value of lease payments, the Company uses its incremental borrowing rate at the lease commencement date because the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the lease payments (e.g., changes to future payments resulting from a change in an index or rate used to determine such lease payments) or a change in the assessment of an option to purchase the underlying asset.

The Company's lease liabilities are included in Interest-bearing loans and borrowings (see Note 32).

2.19 Cash and cash equivalent

Cash and cash equivalents in the balance sheet comprise cash at banks and on hand and short-term deposits with an original maturity of three months or less, which are subject to an insignificant risk of changes in value.

2.20 Operating Cycle

Based on the nature of products / activities of the Company and the normal time between acquisition of assets and their realisation in cash or cash equivalents, the Company has determined its operating cycle as 12 months for the purpose of classification of its assets and liabilities as current and non-current.

M

A

Note 3: Property, Plant and equipment, Capital work in progress & Other Intangible assets
All amounts are in Tenth Lakhs unless stated otherwise.

Particulars	As at	
	31 March, 2020	31 March, 2019
Carrying Amount of:		
Freehold land	7,08,480	7,08,480
Factory Building	41,07,179	43,53,953
Furniture and fixtures	24,540	26,446
Office equipments	99,727	60,565
Computers	95,932	60,964
Plant and machinery	48,40,330	55,15,726
ROU Lease Asset	8,64,513	-
Vehicles	33,15,203	35,74,875
Capital work-in-progress	1,41,45,963	1,43,91,007
Acquired software	2,74,911	3,57,699
Total	1,44,20,875	1,49,61,080

Cost or deemed cost	Tangible asset							Intangible asset	Total	
	Free hold land	Factory Building	Furniture and fixtures	Office equip.	Computer	Plant and machinery	ROU Lease Asset			Vehicles
Balance as on 01 April, 2018	7,08,480	38,51,980	4,50,376	1,81,902	1,76,153	95,85,092	-	42,70,637	48,713	1,29,64,342
Additions	-	-	12,548	14,025	38,236	6,33,879	-	16,89,425	8,813	36,41,499
Deletions	-	-	-	-	-	-	-	4,93,998	-	4,93,998
Balance as on 31 March, 2019	7,08,480	38,51,980	4,62,924	1,95,927	2,14,389	1,02,19,871	-	54,66,065	57,526	2,25,11,743
Balance as on 01 April, 2020	7,08,480	38,51,980	4,62,924	1,95,927	2,14,389	1,02,19,871	-	54,66,065	57,526	2,25,11,743
Additions	-	-	4,938	74,223	80,105	4,48,341	9,75,828	1,72,685	4,36,265	36,15,386
Deletions	-	-	-	-	-	-	-	2,38,763	-	2,38,763
Balance as on 31 March, 2020	7,08,480	38,51,980	4,67,862	2,70,150	2,94,494	1,06,68,212	9,75,828	60,79,087	4,93,790	2,53,68,368

Accumulated Depreciation	Tangible asset							Intangible asset	Total	
	Free hold land	Factory Building	Furniture and fixtures	Office equip.	Computer	Plant and machinery	ROU Lease Asset			Vehicles
Balance as on 01 April, 2018	-	4,01,137	4,27,927	94,963	1,05,143	35,55,558	-	11,84,201	14,575	58,63,504
Depreciation / amortisation expenses for the year	-	3,61,472	8,551	46,400	48,283	1,14,827	-	9,71,583	30,606	25,09,492
Deletions	-	-	-	-	-	-	-	2,64,594	-	2,64,594
Balance as on 31 March, 2019	-	7,62,609	4,26,478	1,41,363	1,53,426	47,04,145	-	18,91,190	45,181	81,08,391
Balance as on 01 April, 2020	-	7,62,609	4,26,478	1,41,363	1,53,426	47,04,145	-	18,91,190	45,181	81,08,391
Depreciation / amortisation expenses for the year	-	3,69,774	6,844	31,061	45,137	1,12,377	1,11,315	16,64,967	1,73,697	29,30,533
Deletions	-	-	-	-	-	-	-	1,91,432	-	1,91,432
Balance as on 31 March, 2020	-	11,32,382	4,33,322	1,72,424	1,98,563	58,17,892	1,11,315	27,64,724	2,18,879	1,08,47,491

Carrying amount	Tangible asset							Intangible asset	Total	
	Free hold land	Factory Building	Furniture and fixtures	Office equip.	Computer	Plant and machinery	ROU Lease Asset			Vehicles
Balance as on 01 April, 2018	7,08,480	33,70,852	22,449	86,939	71,010	60,30,434	-	30,86,437	34,138	1,35,00,738
Additions	-	12,44,572	12,548	14,025	38,236	6,33,879	-	16,89,425	8,813	36,41,499
Deletions	-	-	-	-	-	-	-	2,29,404	-	2,29,404
Depreciation expenses	-	3,61,472	8,551	46,400	48,283	1,14,827	-	9,71,583	30,606	25,09,492
Balance as on 31 March, 2019	7,08,480	43,53,953	26,446	60,565	60,964	55,15,726	-	35,74,075	12,344	1,44,03,351
Balance as on 01 April, 2020	7,08,480	43,53,953	26,446	60,565	60,964	55,15,726	-	35,74,075	12,344	1,44,03,351
Additions	-	1,23,000	4,938	74,223	80,105	4,48,341	9,75,828	1,72,685	4,36,265	30,13,386
Deletions	-	-	-	-	-	-	-	67,330	-	67,330
Depreciation expenses	-	3,69,774	6,844	31,061	45,137	1,12,377	1,11,315	16,64,967	1,73,697	29,30,533
Balance as on 31 March, 2020	7,08,480	41,07,179	24,540	99,727	95,932	48,40,330	8,64,513	33,15,203	2,74,911	1,44,20,875

Provet Veteriner Ürünleri San. ve Tic. A.Ş.
Notes to accounts for the year ended 31st March 2020
All amounts are in Turkish Lira unless stated otherwise

Notes	Particulars	As at 31 March 2020	As at 31 March 2019
4	Non-current Investments		
	Investments in equity instruments of Subsidiary	1,34,50,000	1,34,50,000
		<u>1,34,50,000</u>	<u>1,34,50,000</u>
5	Inventories (At lower of cost and net realisable value)		
	Raw materials and packing materials	1,42,17,650	96,08,429
	Work-in-progress and intermediates	2,18,601	-
	Finished goods	45,17,096	34,00,251
		<u>1,89,53,347</u>	<u>1,30,08,680</u>
6	Current Investments		
	Investments in Mutual funds	16,50,260	1,07,554
		<u>16,50,260</u>	<u>1,07,554</u>
7	Trade receivables		
	Unsecured, considered good	3,49,71,921	2,59,12,950
	Unsecured, considered doubtful	12,63,940	-
		<u>3,62,35,861</u>	<u>2,59,12,950</u>
	Less: Allowances for doubtful debts	(12,63,940)	-
		<u>3,49,71,921</u>	<u>2,59,12,950</u>
8	Cash and cash equivalents		
	Cash on hand	7,097	20,741
	Balances with banks		
	- In current accounts	22,01,639	12,03,728
	- In deposit accounts	97,23,496	1,07,42,776
		<u>1,19,32,232</u>	<u>1,19,67,244</u>
9	Loans		
	Unsecured, considered good:-		
	Advances to employees	98,924	1,93,115
	Loans & Advances to related parties	37,39,112	-
		<u>38,38,036</u>	<u>1,93,115</u>
10	Other current assets		
	Advance to supplier	3,42,262	3,37,010
	Balances with government authorities	4,19,301	8,92,724
	Prepaid expenses	2,08,694	1,29,617
	Others	59,813	44,833
		<u>10,30,070</u>	<u>14,04,183</u>

12

AK

Provet Veteriner Ürünleri San. ve Tic. A.Ş.
Notes to accounts for the year ended 31st March 2020
All amounts are in Turkish Lira unless stated otherwise

Notes	Particulars	As at 31 March 2020		As at 31 March 2019	
11	Share capital				
(a)	Authorised 200 equity shares of TRL 10,000		20,00,000		20,00,000
(b)	Issued, Subscribed and fully paid up 200 equity shares of TRL 10,000		20,00,000		20,00,000
			<u>20,00,000</u>		<u>20,00,000</u>
	Notes:				
	(i) Reconciliation of the number of shares and amount outstanding at the beginning and at the end of the reporting period:				
	Particulars	As at 31 March 2020		As at 31 March 2019	
	Equity shares	Nos of Shares	Amount	Nos of Shares	Amount
	Shares outstanding at the beginning of the period	200	20,00,000	200	20,00,000
	Add: Shares issued during the period				
	Shares outstanding at the end of the period	<u>200</u>	<u>20,00,000</u>	<u>200</u>	<u>20,00,000</u>
	(ii) Terms/rights attached to equity shares				
	In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the company, after distribution of all preferential amounts, if any. The distribution will be in proportion to the number of equity shares held by the shareholders.				
	(iii) Details of shares held by each shareholder holding more than 5% shares				
	Equity shares	As at 31 March 2020		As at 31 March 2019	
		Nos of Shares	% of Holding	Nos of Shares	% of Holding
	Alivra Animal Health Ltd, Ireland	120	60%	120	60%
	Dr. Haseyin Aydin	80	40%	80	40%
12	Other Equity				
	Retained Earnings				
	Opening Balance		29,35,790		52,72,485
	Profit for the year		77,05,367		(22,13,956)
	Remeasurement Benefit		(1,43,271)		(1,22,739)
	Lease as per IND AS 116		(3,23,575)		-
	Deferred Tax on lease		71,187		-
	Closing Balance		<u>1,02,45,497</u>		<u>29,35,790</u>
	(b) Other Reserves				
	General reserve		1,22,53,825		1,22,53,825
	Revaluation Reserve		51,82,487		51,82,487
	Capital reserve		49,339		49,339
			<u>1,74,85,650</u>		<u>1,74,85,650</u>
	Other Equity (Total)		<u>2,77,31,147</u>		<u>2,04,21,440</u>
13	Non-current liabilities - Financial Liabilities				
	From banks				
	Secured		5,24,875		-
	(Halk Bank - Loan obtained for purchase of 7 Vehicles at the interest rate of 10% PA, Repayable in 7 installments)				
			<u>5,24,875</u>		<u>-</u>
14	Long term provisions				
	Provision for employee benefits				
	(i) Provision for gratuity (net)		6,52,763		4,37,722
	(ii) Provision for compensated absences		1,07,955		37,500
			<u>7,60,698</u>		<u>4,75,222</u>

M

OK

Provet Veteriner Ürünleri San. ve Tic. A.Ş.
Notes to accounts for the year ended 31st March 2020
All amounts are in Turkish Lira unless stated otherwise

Notes	Particulars	As at 31 March 2020	As at 31 March 2019
15	Current liabilities- Short term borrowings		
	(a) Loans repayable on demand		
	From banks		
	Secured	74,50,803	81,38,666
	(b) Loan from other related parties		
	Unsecured	3,77,97,176	3,16,45,049
		<u>4,52,47,978</u>	<u>3,97,83,715</u>
16	Current - Trade payable		
	Trade payable	1,63,74,869	1,41,47,891
		<u>1,63,74,869</u>	<u>1,41,47,891</u>
17	Current - Other financial liabilities		
	Current maturities of long-term debt	4,75,125	2,72,108
		<u>4,75,125</u>	<u>2,72,108</u>
18	Other Current liabilities		
	Statutory remittances	4,01,987	5,29,795
	Advances from customers	1,55,296	6,79,455
	Others	20,95,940	13,82,596
		<u>26,53,223</u>	<u>25,91,847</u>
19	Short term provisions		
	Provision for compensated absences	11,890	-
	Provision for gratuity	1,23,604	39,869
		<u>1,35,494</u>	<u>39,869</u>
20	Deferred tax liabilities (net)		
	On account of Leases	(84,479)	-
	Others	6,01,697	9,53,372
		<u>5,17,218</u>	<u>9,53,372</u>
21	Current tax liabilities (net)		
	Provision for taxation	25,77,606	3,19,313
		<u>25,77,606</u>	<u>3,19,313</u>

Handwritten signature or mark.

Handwritten mark.

Provet Veteriner Ürünleri San. ve Tic. A.Ş.
Notes to accounts for the year ended 31 March 2020
All amounts are in Turkish Lira unless stated otherwise

Notes	Particulars	Year Ended 31 March 2020	Year Ended 31 March 2019
22	Revenue from operations		
	Sale of products	7,21,10,399	4,53,00,736
	Other operating revenues	77,07,102	9,29,988
		7,98,17,501	4,62,30,724
23	Other Income		
	Interest income	2,84,630	3,81,810
	Net gain on sale of investments	92,081	1,30,424
	Net gain on sale of fixed asset	2,26,032	2,74,053
	Miscellaneous Income	7,74,529	11,01,828
		13,77,273	18,88,115
24	Cost of materials consumed		
	Opening stock	96,08,429	69,10,746
	Add: Purchases	3,58,47,015	1,64,31,796
	Less: Closing stock	1,42,17,650	96,08,429
		3,12,37,794	1,37,34,113
25	Changes in inventories of finished goods and work-in-progress & intermediates		
	Opening stock		
	Work-in-progress and intermediates	2,53,569	2,53,569
	Finished goods	59,67,225	59,67,225
		62,20,794	62,20,794
	Work-in-progress and intermediates	-	-
	Finished goods	34,00,251	34,00,251
		34,00,251	34,00,251
	Net (increase) / decrease	28,20,543	28,20,543
26	Employee benefits expense		
	Salaries and wages	96,90,895	70,87,460
	Contribution to provident and other funds	21,45,221	14,82,469
	Staff welfare expenses	10,91,924	7,69,053
	Gratuity	2,47,097	1,89,803
		1,31,75,137	95,28,785
27	Finance costs		
	Interest expense	15,59,008	13,42,891
	Lease Interest costs	3,04,031	-
		18,63,039	13,42,891

Provet Veteriner Ürünleri San. ve Tic. A.Ş.
Notes to accounts for the year ended 31 March 2020
All amounts are in Turkish Lira unless stated otherwise

Notes	Particulars	Year Ended 31 March 2020	Year Ended 31 March 2019
28	Depreciation and amortization expense		
	Tangible assets	26,47,970	24,78,875
	Intangible assets	1,71,247	30,606
	Lease Assets	1,11,315	
		<u>29,30,533</u>	<u>25,09,482</u>
29	Other expenses		
	Travel expenses	10,88,829	9,41,502
	Communication expenses	1,97,075	1,95,391
	Consumables	4,97,086	2,06,562
	Contract labour charges	-	13,050
	Legal and Professional charges	5,86,779	3,23,502
	Freight and forwarding	7,14,753	7,96,067
	Power and fuel	10,47,824	6,43,858
	Rent	4,965	6,32,188
	Analytical charges	5,29,147	3,35,684
	Repairs to buildings	1,33,989	1,82,547
	Repairs to machinery	4,20,954	2,96,796
	Repairs to others	9,00,008	3,23,664
	Insurance	1,99,074	1,40,380
	Commission on sales	-	3,751
	Advertisement and selling expenses	36,95,845	13,54,198
	Rates and taxes	5,15,181	5,50,494
	Net loss on foreign currency transactions and translation	57,26,223	1,09,37,045
	Provision for doubtful trade receivables	12,63,940	-
	Other expenses	18,61,694	11,71,865
		<u>1,93,83,365</u>	<u>1,90,48,545</u>
30	Tax expense		
	Current tax	24,43,963	3,19,313
	Deferred tax	(3,64,967)	12,81,350
	Prior period tax	-	(2,52,226)
		<u>20,78,996</u>	<u>13,48,437</u>





Provet Veteriner Ürünleri San. ve Tic. A.Ş.
Notes to accounts for the year ended 31 March 2020
All amounts are in Turkish Lira unless stated otherwise

Note 31 Details of leasing arrangements

The Company's significant leasing arrangement is mainly in respect of office premises, Guest house & Server; the aggregate lease rent payable on these leasing arrangements charged to Statement of Profit and Loss is TRY 359,892

The following is the movement in lease liabilities during the year ended 31 March

Balance as at 1 April 2019	12,99,403
Accretion of interest	3,04,031
Payments	(3,54,927)
Balance as at 31 March 2020	12,48,507
Current	64,399
Non-current	11,84,108

The effective interest rate for lease liabilities is 24%, with maturity till Mar,2029

The following are the amounts recognised in profit or loss:

	Year ended 31 March 2020
Depreciation expense of right-of-use assets	1,11,315
Interest expense on lease liabilities	3,04,031
Deferred tax leases	(13,292)
Total amount recognised in profit or loss	4,02,054

Note 32 Earnings per share

Particulars	Year ended 31st March 2020	Year ended 31st March 2019
Net profit / (loss) for the period as per statement of profit and loss	77,05,367	(22,13,956)
Net profit / (loss) for the period attributable to the equity shareholders	77,05,367	(22,13,956)
Weighted average number of equity shares	200	200
Earnings / (Loss) per share - Basic	38,526.83	(11,069.78)
Earnings / (Loss) per share - Diluted	38,526.83	(11,069.78)

14

At

Note 33 Contingent liabilities and commitments

(i) **Contingent liabilities**

There is no contingent liabilities as on 31st March 2020 & 31st March 2019

(ii) **Commitments**

Estimated amount of contracts remaining to be executed on capital account and not provided for (net of advances)

	Year ended 31st March 2020	Year ended 31st March 2019
Tangible Fixed assets	Nil	Nil

Note 34 Details on derivatives instruments and unhedged foreign currency exposures

The year-end foreign currency exposures that have not been hedged by a derivative instrument or otherwise are given below:

Foreign currency	As at 31st March 2020	As at 31st March 2019
USD		
Receivable	21,26,751	24,86,013
Payable	(74,07,039)	(70,85,706)
Net exposure in USD	(52,80,288)	(45,99,693)
EURO		
Receivable	4,196	34,879
Payable	(12,38,627)	(12,39,378)
Net exposure in EURO	(12,34,431)	(12,04,499)

Provet Veteriner Ürünleri San. ve Tic. A.Ş.

Notes to accounts for the year ended 31 March 2020

All amounts are in Turkish Lira unless stated otherwise

Note 35 - Segment Information

Segments have been identified taking into account the nature of services, the differing risks and returns, the organisational structure and the internal reporting system

Primary segment: Business segment

The Company is mainly engaged in the business of manufacturing and marketing of Vet Pharmaceutical products. Considering the nature of business and financial reporting of the Company, the Company has only one business segment viz; Vet formulation as primary reportable

Secondary Segment Information (Geographical Segment)

Particulars	Year Ended 31 March 2020	Year Ended 31 March 2019
Revenue from operation		
Europe	4,19,613	1,35,819
Asia	7,68,68,331	4,21,86,729
Rest of the World	25,29,557	39,08,177
Total	7,98,17,501	4,62,30,724
Segment Assets		
Europe	39,950	77,867
Asia	9,87,96,151	8,06,26,501
Rest of the World	14,10,639	3,00,408
Total	10,02,46,740	8,10,04,777
Cost incurred during the year to acquire segment assets (tangible and intangible fixed assets)		
Asia	30,15,386	36,41,499
Total	30,15,386	36,41,499

Provet Veteriner Ürünleri San. ve Tic. A.Ş.
Notes to accounts for the year ended 31 March 2020
All amounts are in Turkish Lira unless stated otherwise

Note 36 - Related Party Disclosures

Holding company:

Alivira Animal Health Limited, Ireland
Alivira Animal Health Limited, India (Holding company of Alivira Animal Health Limited, Ireland)
Sequent Scientific Limited, India (Ultimate Holding Company)

Wholly owned Subsidiary :

Topkim-Topkapi İlaç Premiks San. Ve Tic. A.Ş.

Key Management Personnel

Dr. Huseyin Aydın
Manish Gupta

A. Transaction during the year	Year ended 31	Year ended 31
Nature of Transactions	March 2020	March 2019
(i) Purchase of materials		
Alivira Animal Health Ltd, India	1,33,564	76,807
Topkim-Topkapi İlaç Premiks San. Ve Tic. A.Ş.	1,17,18,062	13,28,689
(ii) Sale of materials		
Topkim-Topkapi İlaç Premiks San. Ve Tic. A.Ş.	1,45,03,259	51,40,814
(iii) Interest on Loan		
Alivira Animal Health Ltd, Ireland	10,82,115	9,35,515
(iv) Income from Car rent cross charge		
Topkim-Topkapi İlaç Premiks San. Ve Tic. A.Ş.	7,92,000	-
(v) Income from Conversion charges cross charge		
Topkim-Topkapi İlaç Premiks San. Ve Tic. A.Ş.	63,50,500	-
(vii) Rent charges for office & warehouse		
Dr. Huseyin Aydın	3,00,000	2,70,000
B. Balance as at balance sheet date:		
(i) Borrowing		
Topkim-Topkapi İlaç Premiks San. Ve Tic. A.Ş.	-	21,41,547
Alivira Animal Health Ltd, Ireland	3,42,40,302	2,85,43,737
Dr. Huseyin Aydın	35,56,874	9,59,764
(ii) Advances given		
Topkim-Topkapi İlaç Premiks San. Ve Tic. A.Ş.	37,39,142	-
(iii) Creditors balance		
Dr. Huseyin Aydın	8,75,000	6,35,000
Alivira Animal Health Ltd, Ireland	1,16,74,289	1,00,36,087

The accompanying notes are an integral part of the financial statements.

As per our report of event date
Deloitte Turkey
Auditors

Place : Istanbul
Date : 8 May 2020

For and on Behalf of the Board of Directors

Manish
Manish Gupta
Director
Thane, 6 May 2020



At